Skip to Content
Diagnosed with AS? Biologics can help >

Tofacitinib Pregnancy and Breastfeeding Warnings

Tofacitinib is also known as: Xeljanz, Xeljanz XR

Tofacitinib Pregnancy Warnings

At high doses, this drug has been shown to be fetocidal and teratogenic in animal studies. There are no controlled data in human pregnancy. To monitor the outcomes of pregnant women exposed to this drug, a pregnancy registry has been established. Patients should be encouraged to enroll in the XELJANZ/XELJANZ XR pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call the toll free number 1-877-311-8972. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

UK: Use is contraindicated. AU, US: Use is not recommended. AU TGA pregnancy category: D US FDA pregnancy category: Not assigned. Risk Summary: This drug was fetocidal and teratogenic in animal studies at exposures higher than the maximum recommended human dose (MRHD). Animal studies have also shown reductions in live litter size, postnatal survival, and pup body weights at exposures higher than the MRHD. Comments: -A pregnancy exposure registry is available. -Based on animal studies, this drug can harm a developing fetus. -Women of childbearing potential should be advised to use effective contraception during therapy and for at least 4 weeks after the last dose. -Based on animal studies, this drug may result in reduced fertility in females of reproductive potential.

See references

Tofacitinib Breastfeeding Warnings

UK: Use is contraindicated. AU, UK: Use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: -This drug is excreted in animal milk at concentrations higher than in maternal serum. -The effects in the nursing infant are unknown.

No information is available on the use of this drug during breastfeeding. This drug should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued. An alternate drug may be preferred.

See references

References for pregnancy information

  1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL:" ([2006]):
  2. "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.

References for breastfeeding information

  1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL:" ([2006]):
  2. "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.